Abiopharma

New Form 10-Q - Edgewise Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001558370-25-010655 Size: 5 MB

New Form 8-K - Barinthus Biotherapeutics plc. Filed: 2025-08-07 AccNo: 0001828185-25-000058 Size: 386 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - Silence Therapeutics plc Filed: 2025-08-07 AccNo: 0000950170-25-104593 Size: 8 MB

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

New Form 8-K - Whitehawk Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104592 Size: 621 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Edgewise Therapeutics - Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

New Form 8-K - Perimeter Solutions, Inc. Filed: 2025-08-07 AccNo: 0001880319-25-000103 Size: 473 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - PepGen Inc. Filed: 2025-08-07 AccNo: 0001193125-25-174982 Size: 262 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - UroGen Pharma Ltd. Filed: 2025-08-07 AccNo: 0001437749-25-025242 Size: 259 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Edgewise Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001104659-25-074987 Size: 296 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

[Press Release] HUTCHMED Reports 2025 Interim Results

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

UroGen Pharma Expands Commercial Portfolio with Launch ofZUSDURI™ and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP